109579-04-6

Basic information

• Product Name: METHYL (R)-2-TOSYLOXY PROPIONATE
• Synonyms: METHYL (R)-2-TOSYLOXY PROPIONATE;Methyl (R)-2-tosyloxyl propionate
• CAS NO: 109579-04-6
• Molecular Formula: C₁₁H₁₄O₅S
• Molecular Weight: 258.29
• Mol File: 109579-04-6.mol
• Article Data: 17

Chemical Properties

• Appearance: /
• CAS DataBase Reference: METHYL (R)-2-TOSYLOXY PROPIONATE(CAS DataBase Reference)
• NIST Chemistry Reference: METHYL (R)-2-TOSYLOXY PROPIONATE(109579-04-6)
• EPA Substance Registry System: METHYL (R)-2-TOSYLOXY PROPIONATE(109579-04-6)

Safety Data

• Hazardous Substances Data: 109579-04-6(Hazardous Substances Data)

Upstream product

• 17392-83-5 (R)-Methyl lactate 
• 98-59-9 p-toluenesulfonyl chloride 
• 7699-00-5 (R)-Ethyl lactate 
• 66648-29-1 methyl 2-{[(4-methylphenyl)sulfonyl]oxy}propanoate 
• 547-64-8 methyl lactate 

Downstream Products

• 1043921-69-2 C₂₀H₂₇ClN₂O₆S 
• 1043916-76-2 methyl (2S)-2-[2,4-dichloro-5-({4-[(E)-2-cyanovinyl]-1,3-dimethyl-1H-pyrazol-5-yl}oxy)phenoxy]propionate 
• 1043921-63-6 C₁₉H₂₅ClN₂O₅ 
• 1043917-78-7 methyl (2S)-2-(2,4-dichloro-5-{[4-(3-hydroxypropyl)-1,3-dimethyl-1H-pyrazol-5-yl]oxy}phenoxy)propionate 
• 1043921-66-9 C₁₉H₂₀BrN₃O₄ 
• 1043917-61-8 methyl (2S)-2-[5-({4-[(E)-2-(aminosulfonyl)vinyl]-1,3-dimethyl-1H-pyrazol-5-yl}oxy)-2,4-dichlorophenoxy]propionate 
• 1043917-60-7 methyl (2S)-2-(5-{[4-((E)-2-{[(tert-butoxycarbonyl)amino]sulfonyl}vinyl)-1,3-dimethyl-1H-pyrazol-5-yl]oxy}-2,4-dichlorophenoxy)propionate 
• 1043916-83-1 methyl (2S)-2-{2,4-dichloro-5-[(4-formyl-1,3-dimethyl-1H-pyrazol-5-yl)thio]phenoxy}propionate 
• 1043915-77-0 methyl (2S)-2-{2,4-dichloro-5-[(4-formyl-1,3-dimethyl-1H-pyrazol-5-yl)(methyl)amino]phenoxy}propionate 
• 1097085-14-7 Methyl (2S)-2-({3'-chloro-4'-[(2,2-dimethylpyrrolidin-1-yl)carbonyl]-5-fluorobiphenyl-2-yl}oxy)propanoate 
• 115880-48-3 S-2-phenoxypropionic acidmethyl ester 
• 130368-69-3 (2R)-2-(4-Toluenesulfonyloxy)propionic Acid 
• 130368-70-6 tert-Butyl (4S)-1-Methyl-3-<(2R)-2-(4-toluenesulfonyloxy)propionyl>-2-oxoimidazolidine-4-carboxylate 
• 136622-17-8 N-<(2R)-2-(4-Toluenesulfonyloxy)propionyl>-L-proline Benzylester 

Relevant articles and documents

Assessing multiple conformations of lanthanide binding tags for proteins using a sensitive19F-reporter

Quantifying the isomeric species of metal complexes in solution is difficult.19F NMR herein was used to determine the abundance of isomeric species and dynamic properties of lanthanide binding tags. The results suggest that19F is an efficient reporter in assessing and screening paramagnetic tags suitable for protein NMR analysis.

Studies on angiotensin converting enzyme inhibitors. V. The diastereoselective synthesis of 2-oxoimidazolidine derivatives

A diastereoselective synthesis of imidapril (1), which is under clinical study as an antihypertensive drug based on its angiotensin converting enzyme (ACE)-inhibitory activity, was established. N-Alkylation of (2S)-2-amino-4-phenylbutyric acid ester (12) with 3-((2R)-2-methane or toluenesulfonyloxypropionyl)-2-oxoimidazolidine derivative (11) diastereoselectively proceeded in an SN2 fashion to afford tert-butyl (4S)-3-[(2S)-2-[N-[(1S)-1-ethoxycarbonyl)-3-phenylpropyl]amino]propionyl]- 1-methyl-2-oxoimidazolidine-4-carboxylate (13), a precursor of 1. Alternatively, benzyl (2S)-2-[N-(1S)-1-(ethoxycarbonyl)-3-phenylpropyl]amino]propionate (15), which is the key building block of 13, was synthesized by the same strategy. This procedure was also applied to the synthesis of enalapril.

Optimization of Orally Bioavailable PI3KδInhibitors and Identification of Vps34 as a Key Selectivity Target

Optimization of a lead series of PI3Kδinhibitors based on a dihydroisobenzofuran core led to the identification of potent, orally bioavailable compound 19. Selectivity profiling of compound 19 showed similar potency for class III PI3K, Vps34, and PI3Kδ, and compound 19 was not well-tolerated in a 7-day rat toxicity study. Structure-based design led to an improvement in selectivity for PI3Kδover Vps34 and, a focus on oral phramacokinetics properties resulted in the discovery of compound 41, which showed improved toxicological outcomes at similar exposure levels to compound 19.